Latest news with #DanielAdams
Yahoo
30-05-2025
- Business
- Yahoo
Clinical Trials Demonstrate Monitoring PD-L1 Upregulation Using LifeTracDx Blood Test Could Support New Treatment Path for Metastatic Triple Negative Breast Cancer
MONMOUTH JUNCTION, N.J., May 30, 2025 /PRNewswire/ -- Creatv Bio, a Division of Creatv MicroTech, Inc. ("Creatv") in collaboration with CytoDyn Inc. ("CytoDyn") presents promising four-year survival rates from a pooled clinical trial analysis of patients with metastatic triple-negative breast cancer ("mTNBC") treated with leronlimab and PD-L1 immune checkpoint inhibitors ("ICI"). Leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, was tested with and without ICIs in n=28 mTNBC patients. Results indicated that leronlimab treatment correlated with increased expression of PD-L1 on circulating tumor associated cells, as measured using the LifeTracDx® blood test from Creatv. The analysis also revealed promising survival observations among patients who experienced a significant increase in PD-L1 expression and subsequently pursued treatment with an ICI. Four year follow-up results were presented at the ESMO Breast Cancer meeting on May 15, 2025 by Dr. Richard Pestell, available here. The LifeTracDx® is a universal cancer blood test that uses both circulating tumor cells (CTCs) and Cancer Associated Macrophage-Like (CAML) cells, macrophages that engulf tumor cells, as sensitive and accurate markers for real-time monitoring of tumor response in cancer patients. In the trials presented at ESMO, results showed that monitoring the expressions of PD-L1 before and after induction of leronlimab using the LifeTracDx® blood test identified upregulation of PD-L1 expression in 76% of patients after therapy induction. In a 4-year overall survival follow-up, 5 of the patients with upregulated PD-L1 detected by LifeTracDx® blood test and treated with the ICIs atezolizumab or pembrolizumab were alive after four years. About Creatv Bio Creatv Bio is a cancer screening and cancer diagnostics company providing testing services to patients and to pharma companies to support drug development from its laboratory in NJ. Creatv's scientists were the first to publish on CAMLs found in the blood of cancer patients. LifeTracDx® blood tests have an array of clinical applications including predicting response to a new therapy in 30 days, providing companion/complementary diagnostics such as PD-L1 using blood samples, providing information about aggressiveness of the cancer, detection of minimal residual disease, early detection of cancer recurrence, and cancer screening. For a complete listing of our journal publications and posters, please visit our website. Creatv contacts:Daniel Adams,Ron Baker Chief Scientific OfficerChief Business Officer dan@ 732-783-7132 (office)301-785-5185 (mobile) View original content to download multimedia: SOURCE Creatv MicroTech, Inc. Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Yahoo
27-03-2025
- Health
- Yahoo
LifeTracDx® Blood Test to be Performed in Key Colorectal Clinical Trial
MONMOUTH JUNCTION, N.J., March 27, 2025 /PRNewswire/ -- Creatv Bio, a Division of Creatv MicroTech, Inc. (Creatv) will be collaborating with CytoDyn Therapeutics Corporation (CytoDyn) to assess patient response to their drug using the LifeTracDx® blood test. CytoDyn has received FDA clearance to initiate a Phase II study of leronlimab in patients with relapsed or refractory micro-satellite stable colorectal cancer (CRC) (NCT06699835). The drug, leronlimab, targets CCR5 marker on the tumor. Creatv will perform the LifeTracDx® liquid biopsy in a number of CytoDyn studies including NCT06699835. The LifeTracDx® test is based on analyzing two biomarkers: (1) circulating tumor cells (CTCs) and (2) Cancer Associated Macrophage-Like (CAML) cells, which are macrophages that engulf tumor cells. Both CTCs and CAMLs contain tumor material. By tracking CTC and CAML counts, and CAML size at various time points, LifeTracDx® can provide prognostic insights and predict treatment response. CytoDyn is also interested in the expressions of CCR5 and PD-L1 markers on the tumor. These markers can change over time. LifeTracDx® can provide this information by a blood test - no tissue is required. The LifeTracDx® assay will help CytoDyn to better evaluate the effectiveness of their drug. About Creatv Bio Creatv Bio is a cancer screening and cancer diagnostics company providing testing services to patients and pharma companies to support drug development from its laboratory in NJ. Creatv's scientists were the first to publish on CAMLs found in the blood of cancer patients. LifeTracDx® blood tests have many applications including predicting response to a new therapy in just 30 days, providing companion diagnostics such as PD-L1 and drug targets using blood instead of tissue, providing information about aggressiveness of the cancer, detection of minimal residual disease, early detection of cancer recurrence, and cancer screening. For a complete listing of our journal publications and posters, please visit our website at For more information contact:Daniel Adams,Ron Baker Chief Scientific OfficerChief Business Officerdan@ (office)301-785-5185 (mobile) View original content to download multimedia: SOURCE Creatv MicroTech, Inc. Sign in to access your portfolio
Yahoo
17-03-2025
- Business
- Yahoo
Tesco awards 5.2% pay rise but axes Sunday bonus
The UK's biggest retailer is to raise store worker pay by 5.2% over the next six months but strip away a 10% premium for working on a Sunday. Tesco said it was to stagger the increase, with the full amount taking effect from the end of August after an initial rise at the end of this month, following talks with the Usdaw union. It marks a £180m investment for Tesco and means its staff will remain comfortably over the new national living wage rate due to take effect on 1 April. Money latest: The first rise also coincides with the hike in employer National Insurance contributions announced in last October's budget. It's set to add £250m a year to Tesco's costs. The company employs more than 300,000 people in the UK. It revealed 400 job losses in January as part of efforts to "simplify" the business ahead of the tax change. The new pay deal, while above the rate of inflation, will remove a 10% bonus enjoyed by staff when they work a shift on a Sunday. Tesco, which had already removed the perk for new starters, said those affected by the loss of pay would receive a one-off payment to cover the next 18 months as it phased out the premium. Tesco UK boss Matthew Barnes said: "Our colleagues are our greatest asset, and this pay deal recognises the brilliant work they put in day-in, day-out to serve our customers. Read more from Sky News:Thames Water avoids imminent government ownershipOdey faces £1.8m fine and City ban for 'lack of integrity'Trump tariffs blamed for global growth downgrades "It also represents another significant investment in our colleague pay, which combined with our fantastic package of benefits, means Tesco continues to be a place to get on and thrive in a fulfilling and rewarding career." Daniel Adams, Usdaw national officer, said of the agreement: "It is a real achievement that Usdaw reps have been able to secure an above-inflation pay deal that builds on the negotiations of the last few years. "Not only does it ensure a meaningful gap between the Tesco rates of pay and the national living wage in April, but it also means that in August, the basic rate of pay in Tesco will exceed the real living wage rate outside of London and meet it within the M25."
Sky News
17-03-2025
- Business
- Sky News
Tesco awards 5.2% pay rise but axes Sunday bonus
Why you can trust Sky News The UK's biggest retailer is to raise store worker pay by 5.2% over the next six months but strip away a 10% premium for working on a Sunday. Tesco said it was to stagger the increase, with the full amount taking effect from the end of August after an initial rise at the end of this month, following talks with the Usdaw union. It marks a £180m investment for Tesco and means its staff will remain comfortably over the new national living wage rate due to take effect on 1 April. The first rise also coincides with the hike in employer National Insurance contributions announced in last October's budget. It's set to add £250m a year to Tesco's costs. The company employs more than 300,000 people in the UK. It revealed 400 job losses in January as part of efforts to "simplify" the business ahead of the tax change. 3:02 The new pay deal, while above the rate of inflation, will remove a 10% bonus enjoyed by staff when they work a shift on a Sunday. Tesco, which had already removed the perk for new starters, said those affected by the loss of pay would receive a one-off payment to cover the next 18 months as it phased out the premium. Tesco UK boss Matthew Barnes said: "Our colleagues are our greatest asset, and this pay deal recognises the brilliant work they put in day-in, day-out to serve our customers. "It also represents another significant investment in our colleague pay, which combined with our fantastic package of benefits, means Tesco continues to be a place to get on and thrive in a fulfilling and rewarding career." Daniel Adams, Usdaw national officer, said of the agreement: "It is a real achievement that Usdaw reps have been able to secure an above-inflation pay deal that builds on the negotiations of the last few years. "Not only does it ensure a meaningful gap between the Tesco rates of pay and the national living wage in April, but it also means that in August, the basic rate of pay in Tesco will exceed the real living wage rate outside of London and meet it within the M25."
BBC News
17-03-2025
- Business
- BBC News
Tesco to raise wages by 5% but scrap Sunday bonus
Tesco will lift pay for its store staff by 5.2% but will scrap the extra pay for working on UK's biggest supermarket chain said the hourly rate will go up by 43p to £12.45 from 30 March after reaching a deal with will raise pay again to £12.64 from the end of August - a little above the UK national minimum wage which is set to rise to £12.21p per hour from Tesco will also drop the current 10% pay bonus for Sunday shifts for all staff, which it had already stopped providing for new starters. Tesco's UK chief executive says the £180m spent on funding the pay increases is a "significant investment".The USDAW union said workers in London will see their pay rate increase to £13.66p per hour, and then £ changes come after discussions with the trade union, and Tesco said the two-phase increase will bring pay 5.2% above Daniel Adams said the above-inflation raise "ensures a meaningful gap between the Tesco rates of pay and the National Living Wage in April".Tesco added that those effected by the scrapping of the Sunday pay bonus will receive a one-off payment, although it did not make clear how much the payment would be nor how it would be move comes as many big supermarkets raise pay to attract more staff in a tight labour January, Sainsbury's said it will raise hourly pay by 5%, also in two phases, but said it was cautious about recruiting new staff in 2025 due to rising costs "to help manage a particularly tough cost inflation environment".The German-owned discount chain Lidl will also raise pay, it announced in February, from £12.40p per hour to £ Rachel Reeves announced in the October Budget that in April, along with the national minimum wage, employer National Insurance contributions will also rise. Businesses have said the extra costs from these changes will mean higher prices, job cuts, and shop closures, though unions have criticised firms for saying this.
